Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (
POL
) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds.
POL
-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-lucifera...
Alternative Titles
Full title
Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4fce68f06fa447a9900416b8a0eff43d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4fce68f06fa447a9900416b8a0eff43d
Other Identifiers
ISSN
1743-422X
E-ISSN
1743-422X
DOI
10.1186/1743-422X-8-40
